SUMMARy
This study evaluated whether perioperative administration of gabapentin in cardiac surgery patients could reduce postoperative opioid consumption, postoperative sleep or perceived quality of recovery. This randomised controlled trial assigned 60 patients undergoing cardiac surgery to receive 1200 mg of gabapentin or placebo two hours preoperatively, and then 600 mg of gabapentin or placebo twice a day for the next two postoperative days. Postoperative opioid use was measured by the amount of fentanyl used in the first 48 hours postoperatively. Pain at rest and with movement at 12, 24, 48 and 72 hours after surgery, sleep scores on postoperative days two and three and patientperceived quality of recovery were also assessed. Fentanyl use, visual analog pain scores, sleep scores, adjunctive pain medication use and number of anti-emetics given were not significantly different between the gabapentin and placebo groups. The incidence of side-effects was similar between the gabapentin and placebo groups, and no difference was found between groups in relation to quality of recovery. These findings indicate that preoperative use of gabapentin followed by postoperative dosing for two days did not significantly affect the postoperative pain, sleep, opioid consumption or patient-perceived quality of recovery for patients undergoing cardiac surgery.
key Words: cardiac surgery, postoperative analgesia, gabapentin cardiac surgical pain has not been investigated previously. In addition, gabapentin has not been evaluated in any patient population that requires the use of extracorporeal circulation, and there are no data or information on the effects of cardiopulmonary bypass (CPB) on gabapentin levels.
The aim of the present randomised, placebocontrolled, double-blind study was to investigate the effect of perioperative gabapentin on postoperative opioid consumption and visual analog scale pain scores at rest and with movement in patients after cardiac surgery. In addition, the study evaluated the effect of gabapentin on other endpoints: postoperative sleep, requirements for additional adjunctive pain medication and patient-perceived quality of recovery after surgery.
MATERIALS AND METHODS
After institutional approval and written informed consent were obtained from all subjects, 60 patients undergoing cardiac surgery via median sternotomy were enrolled between July 2006 and June 2008. All patients approached to partake in this study agreed to do so. Exclusion criteria were categorised as: 1) Preoperative: patients with allergy to gabapentin, age greater than 75 years or less than 18 years, body mass index greater than 40 kg/m 2 , presence of a chronic pain disorder, substance abuse or major psychiatric disorder, previous treatment with gabapentin, renal insufficiency (serum creatinine greater than 150 µmol/l), liver insufficiency (ALT or AST greater than two times the upper limit of normal), seizure disorder, left ventricular ejection fraction less than 40%, emergency surgery, coagulopathy, recent (within prior 48 hours) myocardial infarction, cerebrovascular accident or transient ischaemic attack within six months, presence of an intraaortic balloon pump; 2) Intraoperative: CPB time greater than three hours, insertion of an intraaortic balloon pump, utilisation of ketamine for anaesthesia induction; 3) Postoperative: symptomatic dysrhythmia, urine output less than 30 ml/hour for more than four consecutive hours, temperature less than 34.9 or greater than 38.5° Celsius, chest tube output greater than 500 ml/hour for more than two hours and use of three or more inotrope infusions.
On the day of surgery, patients were randomly assigned to receive either gabapentin 1200 mg per oram or matched placebo approximately two hours prior to surgical incision. The gabapentin and placebo capsules were prepared by the hospital pharmacy and were identical with respect to shape, size and colour. The patients were randomised using a computer-generated table of random numbers maintained in the pharmacy. Postoperatively the study drug was then administered orally in the morning and evening at half the dose (gabapentin 600 mg or matched placebo) for the next two days. This dose of gabapentin was chosen based on the effectiveness of preoperative gabapentin in other dose-finding studies [12] [13] [14] [15] 26, 27 . Upon arrival in the intensive care unit (ICU) all patients were started on a fentanyl patient-controlled analgesia pump (PCA) as the primary postoperative pain medication, and all nurse/physician-directed pain medication prior to extubation was delivered via the PCA. The PCA was discontinued at 48 hours postoperatively and the patient was changed to oral opioids. In addition to the study medication, all patients received 1 g of paracetamol four times daily. The investigators, surgical and anaesthesia personnel, ICU physicians and perioperative nurses and healthcare workers were blinded to the group assignment. Unblinding occurred only at the completion of the study.
Preoperative cardiac medications were continued until the time of surgery. Other preoperative medications permitted in the study were ranitidine, metoclopramide, temazepam, diazepam, scopolamine and morphine (up to 10 mg) at the discretion of the attending anaesthetist. Intraoperatively, patients received a balanced anaesthetic at the discretion of the anaesthetist, with fentanyl, midazolam, propofol or thiopentone, for induction; a muscle relaxant; propofol and/or sevoflurane and/ or isoflurane for maintenance with a BIS monitor (A-2000 Standard System, Aspect Medical Systems, Norwood, MA, USA) for detection of awareness. All patients underwent surgery on CPB utilising membrane oxygenators, haemodilution and mild to moderate hypothermia, and were extubated postoperatively in the ICU. There was no limitation on the site of graft harvest for these patients, though all had saphenous vein harvesting performed for acquisition of conduit in addition to median sternotomy.
The primary outcome measure for comparing gabapentin versus placebo was the amount of fentanyl consumed by PCA in the first 48 hours postoperatively. Additional assessments included a measure of pain at rest (supine with head of bed at 20 degrees) and with movement (sitting and using an incentive spirometry device) assessed by nursing staff at 12, 24, 48 and 72 hours postoperatively on a 10 point visual analog scale (VAS) (0=no pain, 10=worst pain ever), number of patients requiring adjunctive pain medications (tramadol, pethidine or nonsteroidal anti-inflammatory drugs), selfevaluation of sleep and sleep satisfaction on postoperative nights two and three, gabapentin-induced side-effectsspecifically dizziness, arrhythmias, diarrhoea and sedation, opioid-induced sideeffects -specifically the number of anti-emetic drugs required over the first postoperative 48hour period; and, as gabapentin has been shown to provide anxiolysis, sedation and improvements in functional recovery, patient assessment of satisfaction with pain control as measured on postoperative day five via a patient-related quality of recovery questionnaire (QoR Score) 19 . The QoR Score is a valid and reliable method of assessing and measuring a patient's postoperative recovery, and encompasses a wide range of patient conditions and surgical procedures 19 . Sleep scores were measured for postoperative days one and two on a numeric scale of 0 to 5 (0=worst sleep ever, 5=best sleep ever). Sedation scores were measured by nursing staff evaluation at 24 and 48 hours on a numeric scale of 0 to 3 (0=patient fully awake, 1=patient sedated but responsive to verbal commands, 2=patient sedated but responsive to tactile stimuli, 3=patient sedated and responsive only to painful stimuli). Dizziness was self-evaluated by the patient on a numeric 1 to 5 scale (1=no dizziness, 5=severe dizziness) for the entire 48-hour study period.
The following information was recorded: demographic data, time under anaesthesia, time on CPB, time to extubation, number of patients who received magnesium and total magnesium dose and number of patients who received one dose of postoperative pethidine for shivering. Magnesium is an N-methyl-D-aspartate receptor antagonist shown to decrease opioid requirements in experimental animal models of pain, yet having both positive and negative effects on pain in a limited number of noncardiac procedures on humans 20, 21 . Magnesium is often given perioperatively in cardiac surgical patients for arrhythmia prevention and membrane stabilisation. It was felt appropriate to monitor the proportion of patients in each group that received magnesium due to the possible anti-nociceptive effect it may possess.
The sample size requirement was determined by drawing on an institutional pilot assessment of fentanyl usage post-cardiac surgery in 30 patients not receiving gabapentin who met the inclusion and exclusion criteria for this study. A reduction of 20% in fentanyl use was deemed to be statistically and clinically significant and would require 60 patients in the total sample (n=30 per group). This estimate provided an 80% chance (power) of detecting a difference with a 5% significance level. Chi-square and two-tailed t-tests were used to assess differences in demographic and perioperative time variables. Between group differences in VAS scores and fentanyl usage were compared at corresponding time intervals using a Mann-Whitney U-test as the data did not follow a normal distribution. Chi-square tests were used to compare the incidence of sideeffects, sleep scores, dizziness scores and adjunctive pain medications used. The only power calculation determined was for the primary outcome of fentanyl usage postoperatively, and all other outcomes are exploratory in nature and should be taken as such. P <0.05 was considered statistically significant.
RESULTS
Sixty patients, 30 per group, were enrolled in the study. Six patients were excluded -three per group -one patient vomited the premedication after concurrently receiving morphine, three patients received their premedication and subsequently had their surgery cancelled due to lack of ICU beds or time overruns on a previous case, and two were excluded as they were also on a separate and conflicting clinical trial that was not noticed when they were enrolled. The two groups were similar with respect to demographic data, the only statistically significant differences being a greater number of patients with diabetes mellitus type 2 in the gabapentin group (40.7%) vs the placebo group (11.1%), and a greater number of patients who received magnesium in the gabapentin group (40.7%) versus the placebo group (18.5%) ( Table 1 ). The placebo and gabapentin groups were similar in relation to time under anaesthesia, time on CPB, time to extubation and number who received a single dose of pethidine for shivering. Total PCA fentanyl usage in the first 48 hours was not significantly different between the placebo and gabapentin groups ( Table 2 ). In addition, there was no significant difference between groups in sleep scores, number of anti-emetics given in the first 48 hours, adjunctive pain medications used and score achieved on the quality of recovery (QoR) questionnaire ( Table 2 ). VAS pain scores recorded at 12, 24, 48 and 72 hours at rest and movement were not significantly different between the gabapentin and placebo groups measuring both median VAS ± range or mean VAS ± standard deviation (Table  3 , Figure 1, Figure 2 ). The incidence of side-effects was not significantly different between groups (arrhythmias, dizziness and sedation, Table 4 ). The only sustained arrhythmias recorded were atrial fibrillation (data not shown).
DISCUSSION
This study demonstrates that the perioperative use of gabapentin does not alter the amount of opioid utilised by patients after cardiac surgery. In addition, for exploratory comparisons between active drug and placebo groups, the VAS pain scores were comparable at rest and with movement for the first three days after surgery. There was no significant difference in patient sleep, or perceived quality of their postoperative care as measured by the Quality of randomised controlled trials and recent metaanalyses have shown that a single preoperative dose of gabapentin may be a useful adjunct for perioperative pain management for other procedures [12] [13] [14] [15] [16] . After ingestion of oral gabapentin, the peak plasma concentrations are obtained within two to three hours, and the drug is then eliminated unchanged in the urine with renal clearance linearly related to creatinine clearance 13, 14 . The dose we utilised in this study is within the limits of a single dose in the treatment of neuropathic pain, and quite consistent with the dosage used in a number of recent clinical trials and dose-finding studies measuring the effect of gabapentin on postoperative pain 18, [22] [23] [24] [25] [26] [27] .
The past few decades have led to significant improvement in the technical aspects of cardiac surgery through better surgical technique, improved myocardial protection on CPB and advances in anaesthetic monitoring and medications. However, pain control postoperatively still utilises opioids as the cornerstone of therapy. As the age of the average patient increases, and comorbid conditions become more prevalent, more therapies will be needed to facilitate early ambulation and preservation of cognitive function. Based on numerous other perioperative studies in non-cardiac surgery, we hypothesised that perioperative gabapentin would both decrease the need for opioids in postoperative cardiac surgery patients, and also attenuate the opioid-related side-effects such as nausea/vomiting and sedation, constipation and ileus, and respiratory depression causing atelectasis and prolonged mechanical ventilation. It has been suggested that after many surgical procedures, acute neuropathic pain and neurologic wind-up is common and, in cardiac surgical patients, dysaesthesia in the early postoperative period often unrelieved by conventional opioid analgesia is a frequent occurrence 2 . Gabapentin has been shown to be effective in the management of this type of pain and as a component of postoperative multimodal analgesia, is an attractive choice for co-analgesia where such diverse nociceptive mechanisms are involved. Despite this, our study did not show any statistically significant beneficial effect of gabapentin on opioid consumption, and the exploratory outcomes of pain scores, sleep scores, quality of recovery as perceived by the patient and mitigation of opioidrelated side-effects.
There are several limitations to the present study. Gabapentin is a medication not bound to plasma proteins after administration and is easily removed by haemodialysis 13 . The CPB machine utilises a membrane oxygenator and a plastic circuit, both of Recovery Score on the fifth postoperative day. There was no increase in the incidence of side-effects for patients on perioperative gabapentin compared with placebo.
Gabapentin is an antiepileptic drug that is a structural analog of gamma-aminobutyric acid. All perioperative applications of gabapentin are currently 'off-label'. However, a number of which can remove free drug from plasma during the many circulations of blood through the CPB circuit. This, along with CPB haemodilution, may have led to a significantly lowered plasma concentration of gabapentin postoperatively compared to previous studies, none of which were undertaken in cardiac surgery, and therefore decreased the amount of gabapentin available to produce an antinociceptive effect. The physical removal of gabapentin from plasma by the CPB circuit is one limitation and the effect of the CPB circuit on the patient may be another. CPB is known to cause neuropsychological changes in all patients, an effect that may alter the mechanism by which gabapentin interacts in the nociceptive pathway. No previous study has looked at gabapentin in patients on CPB; therefore there is no corroborating or conflicting evidence to allow a determination on how CPB affects gabapentin and pain pathways. Another limitation involves the time between the initial dose of gabapentin and the patient wakening from surgery in the ICU. In patients with normal renal function, the elimination of gabapentin when administered as a single agent is between five and nine hours 13 . The time between premedication and wakening was (average for both groups) 9.4 hours. Given the duration of surgery and the expected half-life of gabapentin it is possible the effect of the medication was significantly waning prior to wakening from the anaesthetic. The characteristics of the population studied may have affected the outcome. Although equally distributed, the male/female ratio for the overall study was skewed to a significantly higher number of males recruited, though this is typical of the cardiac surgery population in Australia. It is possible that gabapentin reacts differently depending upon the gender of the patient receiving the medication, although this was not found in any other study into the perioperative use of gabapentin. Finally, the size of the sample population studied was a limitation. Due to patient exclusions, two of which happened post-study completion when it was determined these patients were in a conflicting and exclusionary pharmaceutical trial, we did not reach our desired sample size. It is possible that a much larger sample size would have produced more complete data and a different result, and that this small study may in fact be underpowered to answer the very question it poses. In addition, as this study was powered to exclude a 20% difference in fentanyl use predetermined as clinically relevant, we cannot exclude that up to a 20% difference may have occurred without being statistically significant. However, even with the inclusion of further patients it is unlikely we would have obtained a positive answer to our hypothesis, as none of the endpoints on which we focused approached significance. Further studies could be undertaken to determine serum level of gabapentin pre-, during and post-CPB; multiple dosing regimens of gabapentin in cardiac surgery; and the long-term pain management and effect on chronic post-surgical pain post-cardiac surgery.
In conclusion, and contrary to our initial hypothesis and a number of previous studies in the literature, patients undergoing cardiac surgery on CPB do not appear to have a reduction in postoperative opioid consumption or pain scores at rest or movement with gabapentin. Gabapentin, in comparison with a placebo, does not appear to improve patient sleep or improve the perceived quality of recovery a patient feels after cardiac surgery. Gabapentin prescribed at this specific dose and dosing schedule is ineffective in aiding to control post-sternotomy pain in cardiac surgical patients.
